ASH 2024 – John Seymour
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationJohn Seymour elucidates the promising outcomes of BTK degraders in hematological malignancies, as for example demonstrated in the CaDAnCe-101 trial, and reflects on their future role in treatment strategies. He delves into the pros and cons of fixed-duration versus continuous therapy in CLL and highlights the clinical significance of clonal hematopoiesis in patients with CLL.